SCHEMBL711626

SCHEMBL711626

Cc1csc(Nc2ccc(S(=O)(=O)Nc3nccs3)cc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
LMNA P02545 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
KDM4E B2RXH2 1/20 0.60
CYP2C9 P11712 1/20 0.60
EDNRA P25101 1/20 0.60
SLC6A4 P31645 1/20 0.60
ADRA1A P35348 1/20 0.60
PRMT6 Q96LA8 1/20 0.60
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
PKM P14618 4/20 0.58
PPIA P62937 2/20 0.58
EGFR P00533 2/20 0.57
KDR P35968 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
CYP1A2 P05177 1/20 0.55
ATM Q13315 1/20 0.55
POLB P06746 1/20 0.53
CCNT1 O60563 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712620 0.86 KMT2A (0.57) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL711424 0.83 SCN3A (0.56) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL712071 0.82 MEN1 (0.58) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL712318 0.81 MEN1 (0.63) ALDH1A1TDP1KDM4EMEN1KMT2A
SCHEMBL3642138 0.81 KMT2A (0.52) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL712098 0.80 PKM (0.52) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL714725 0.80 SCN8A (0.60) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL713208 0.80 ADRB2 (0.57) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL13452528 0.79 MEN1 (0.71) ALDH1A1LMNATDP1KDM4ECYP2C9
SCHEMBL8388562 0.79 PPIA (0.76) ALDH1A1LMNATDP1KDM4ECYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A ALDH1A1 3333/4885LMNA 2921/4885TDP1 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.